Hyderabad-based bio-pharmaceuticals company Shantha Biotechnics Limited, producer of the country's first genetically-engineered recombinant vaccine, has so far sold over 250 million doses of Shanvac-B. | |
| The Hepatitis-B vaccine was developed by the company a decade ago. Used in the prevention of liver infection that can lead to liver failure or cancer, Shanvac-B is also the first Indian Hepatitis-B vaccine to be pre-qualified by the World Health Organisation (WHO). |
| |
| Speaking in connection with the completion of 10 years of the Shanvac vaccine on Saturday, Varaprasad Reddy, managing director of Shanta Biotec, however, expressed his unhappiness with the Government of India agencies for not including the Hepetitis-B vaccine in the standard list of vaccine usage in public health facilities till recently. |
| |
| "The company is surviving only on exports. While people in many countries are benefiting from the drastic reduction in cost of vaccines like Hepatitis-B, India, however, did not allow the people of the country to enjoy such benefits," he said. |
| |
| The closely-held company expects its revenues to cross Rs100-crore during the current financial year, from Rs 80 crore last year. |
| |
|
| |
